Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chemotherapy + platinum agent refers to a combination cancer treatment regimen that includes a platinum-based chemotherapeutic drug (such as cisplatin, carboplatin, or oxaliplatin) together with one or more other cytotoxic agents. Platinum agents are coordination complexes of platinum and act primarily by forming DNA crosslinks that inhibit DNA repair and synthesis, leading to apoptosis in rapidly dividing cells. These regimens are widely used for various solid tumors including lung, ovarian, testicular, colorectal, head and neck cancers among others. The specific non-platinum drugs combined with the platinum agent vary depending on the cancer type and clinical protocol[2][3][4][5][6]. Platinum agents are considered "alkylating-like" due to their mechanism but do not contain alkyl groups[3]. Commonly used combinations include cisplatin or carboplatin with drugs such as paclitaxel, etoposide, pemetrexed or gemcitabine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chemotherapy + platinum agent.